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Abstract 
Two synthetic aziridinomitosenes (AZMs), Me-AZM and H-AZM, structurally related to mitomycin C (MC) 
were evaluated for their anticancer activity against six cancer cell lines (HeLa, Jurkat, T47D, HepG2, HL-60, 
and HuT-78) and tested for their DNA-modifying abilities in Jurkat cells. Cytotoxicity assays showed that Me-
AZM is up to 72-fold and 520-fold more potent than MC and H-AZM, respectively. Me-AZM also 
demonstrated increased DNA modification over MC and H-AZM in alkaline COMET and Hoechst 
fluorescence assays that measured crosslinks in cellular DNA. Me-AZM and H-AZM treatment of Jurkat cells 
was found to sponsor significant DNA-protein crosslinks using a K-SDS assay. The results clearly indicate that 
the AZM C6/C7 substitution pattern plays an important role in drug activity and supports both DNA-DNA and 
DNA-protein adduct formation as mechanisms for inducing cytotoxic effects.  
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1. Introduction 
DNA-modifying agents are an important and valuable class of drugs used in conventional chemotherapy. 
Mitomycin C (MC, see Figure 1), a natural product first isolated from the soil bacteria Streptomyces 
caespitosus,1 is a member of this class and has historically had a role in the treatment of a number of cancers, 
including colorectal, gastric, bladder, lung, head and neck, and non-small-cell lung cancers.2,3 MC requires 
intracellular activation by diaphorase,4 cytochrome P450 reductase,5 or other 1- or 2-electron reductases,6 to 
form MC-leucoaziridinomitosene (Figure 1), the fate of which depends upon the activation conditions. Under 
conditions of fast MC reduction, low concentration, and acidic pH, bifunctional activation of the MC-
leucoaziridinomitosene is favored,7 which exerts antitumor effects through creation of DNA interstrand 
crosslinks (ICLs) that prevent DNA replication and cause cell death.8,9 The sequence involves acid-catalyzed 
aziridine ring opening of the MC-leucoaziridinomitosene to form an initial leucoaziridinomitosene-DNA 
monoadduct. Ensuing carbamate departure and subsequent nucleophilic attack, followed by oxidation, results in 
the MC-DNA ICL structure.  
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Figure 1. Mechanism for MC activation that results in DNA ICLs (via bifunctional activation pathway) and DNA monoadducts (via 
monofunctional activation pathway). 
Under conditions of slow MC reduction, high drug concentration, or higher pH, the hydroquinone moiety in the 
leucoaziridinomitosene re-oxidizes to yield the MC-AZM quinone structure that undergoes monofunctional 
activation (Figure 1).7,10,11 MC-AZM is proposed to primarily cause DNA monoalkylation at C1 through acid-
activation to produce a protonated aziridine that ring opens to relieve the strain associated with the three-
membered ring.12 The presence of the adjacent electron deficient quinone moiety in the MC-DNA monoadduct 
disfavors expulsion of the C10 carbamate group that is necessary to create the ICL. Further, the location of the 
MC-DNA monoadduct within the DNA minor groove is thought to sterically hinder additional enzymatic 
reduction of the quinone ring, which is essential for carbamate departure.13-15  
The mechanism of AZM-sponsored DNA monoalkylation is generally well accepted. However, in contrast to 
previous AZM studies, the synthetic C6/C7 unsubstituted (1S,2S)-6-desmethyl(methylaziridino)mitosene (H-
AZM, Figure 2) was shown to crosslink DNA in the absence of an exogenous reductant.16 Instead, H-AZM bis-
alkylated self-complementary DNA with the 5'-d(CG) dinucleotide sequence as the minimum common element. 
ICL production was optimal at pH 6 and overall yield increased with reaction time (up to 48 hours). H-AZM 
treatment of duplex DNA containing the inverted 5'-d(GC) dinucleotide sequence resulted in no detectable ICL 
product. Similarly, H-AZM treatment failed to crosslink DNA sequences where the dG residues were replaced 
with 2'-deoxyinosines (dI) that lack the exocyclic C2 amino group in the purine ring. Thus, H-AZM appears to 
mediate dG-dG nucleobase ICL in the minor groove of the DNA duplex, but via an as yet unknown mechanism.  
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Figure 2. Structures of H-AZM and Me-AZM.  
In a DNA footprinting/UvrABC nuclease assay used to examine H-AZM modification of a 129-base pair DNA 
fragment, the autoradiogram displayed bands corresponding to DNA adducts with molecular weights higher 
than the starting DNA fragment.17 Notably, one of the bands increased upon addition of the nuclease and, 
consequently, it was speculated that H-AZM was facilitating the formation of covalent DNA-protein crosslinks 
(DPCs). In the same experiments, an AZM derived from mitomycin A did not produce analogous adducts. 
Besides this tentative evidence, to the best of our knowledge, there are no other literature reports of AZMs 
forming DPCs. However, MC has been shown to facilitate the crosslinking of actin to DNA in human leukemia 
and myeloma cells.18-20  
In this study, we evaluate the cellular toxicity of H-AZM and its C6 methyl derivative Me-AZM (Figure 2).17 
Cytotoxicity was tested against a panel of six different human cancer cell lines (3 adherent and 3 non-adherent) 
using a resazurin reduction assay to evaluate cell viability and proliferation. Mechanistic studies were 
performed to evaluate AZM-induced DNA interactions. Me-AZM- and H-AZM-treated Jurkat cancer cells 
were analyzed by single cell gel electrophoresis (COMET), Hoechst 33342 staining, and K-SDS DNA-Protein 
crosslinking assays to assess the formation of DNA-DNA and DNA-protein adducts.  
2. Results/Discussion 
2.1 Resazurin reduction assay and AZM stability 
The cytotoxic effects of Me-AZM, H-AZM, and MC against cancer cell cultures were determined using a 
resazurin reduction assay that follows the conversion of blue non-fluorescent resazurin to pink fluorescent 
resorufin that occurs in healthy metabolically active cells.20,21 The antiproliferative effects of Me-AZM, H-
AZM, and MC against six human cancer cell lines are summarized in Table 1 (see supplemental content for 
representative cytotoxicity profiles). All three compounds produced drug IC50 values that ranged from low 
nanomolar to low micromolar concentrations. 
Table 1. Summary of drug antiproliferative effects.  
                                                                                                           Mean IC50  (± SEM) (nM)a 
Cell line Type Adherent/ Suspension MC H-AZM Me-AZM 
HeLa Cervical Adenocarcinoma Adherent   1,870  ±    372 6,208  ±    523 525  ±  242 
HepG2 Hepatocellular Carcinoma Adherent   2,937  ±    209 7,870  ±    701 342  ±    73 
T47D Breast Ductal Carcinoma Adherent 16,970  ± 1,472 9,291  ± 1,516 225  ±    78 
HL-60 Acute Promyelocytic Leukemia Suspension      410  ±      86  2,033  ±    967   30  ±      5 
HuT-78 Cutaneous T-Cell Lymphoma Suspension        66  ±      33    131  ±      48   24  ±    16 
Jurkat T-Cell Leukemia Suspension      578  ±      67 4,160  ±    530     8  ±      6 
Jurkat T-Cell Leukemia (hypoxic) Suspension      303  ±    131 3,965  ±    527     4  ±      2 
aIC50 values represent the mean (± SEM) of three independent experiments (with at least n = 3 for each experiment). 
 
Me-AZM was at least 2.75 times more active than MC and at least 5.5 times more active than H-AZM against 
every cell line. The difference was most notable in Jurkat cells, where Me-AZM was 72-fold more potent than 
MC and 520-fold more potent than H-AZM. Overall, the quinone-unsubstituted H-AZM was the least toxic of 
the three compounds, with IC50 values that were typically 2- to 13-fold lower than those of MC, although it 
showed greater activity against T47D cells. Also, the three compounds were not as effective against adherent 
cancer cell lines, displaying activity that was in the low micromolar range for MC and H-AZM (IC50 = 2-17 
µM) and the sub-micromolar range for Me-AZM (IC50 = 0.2-0.5 µM). 
The increased potency of Me-AZM over MC and H-AZM may be due to presence of the methyl group at C6, 
lack of a hydrophilic amine group at C7, and methylation of the aziridine ring that may improve the 
electrophilic integrity of the AZM and stabilize the molecule for productive reactions with cellular nucleophiles. 
Alternatively, evidence suggests that H-AZM is inherently more reactive than other AZMs, especially under 
basic/nucleophilic conditions, and this may account for its decreased potency. For example, H-AZM was 
reported to decompose to unidentifiable products in basic methanol solutions in a manner that was consistent 
with 1,4-addition (i.e., Michael addition) of an oxygen nucleophile into the quinone ring.17 In analogous 
experiments, AZMs derived from MC underwent only aziridine ring-opening.12 However, H-AZM was more 
stable than the other tested compounds in neutral and mildly acidic methanolic solutions.17 
To examine whether drug instability could explain the differences in drug IC50 results, the decomposition of  
Me-AZM and H-AZM in cell culture media (DMEM + 10% FBS) was monitored via HPLC (see supplemental 
content). The results indicate that H-AZM decomposes rapidly in culture media, with only 10% of the 
compound remaining after 2 hours. In contrast, Me-AZM was more stable, with 90% of the compound 
remaining after 2 hours. Further, chromatograms suggest AZMs decompose to large molecular weight 
components that overlap with contents of the cell culture media. These results, taken together with the methanol 
solvolysis experiments,17 suggest that H-AZM is more susceptible to base or nucleophile-mediated 
decomposition that most likely occurs via nucleophilic addition at C6 and/or C7. Bionucleophiles (e.g., amino 
acids, albumin, etc.) present in the cellular media probably sequester H-AZM before it reaches a significant 
cellular target, thus mitigating its overall cytotoxicity.  
Although Me-AZM was consistently more potent than MC, the resazurin reduction assays were conducted 
under aerobic conditions. Given MC’s requirement for reductive activation and reported increased efficacy 
against hypoxic cells,23 we evaluated the antiproliferative effects of Me-AZM, H-AZM, and MC against Jurkat 
T-cell leukemia cells that were first incubated in a 95% N2/5% CO2 environment and then in a hypoxic 
chamber for the duration of the experiment. Under these conditions, a slight but statistically insignificant 
increase in potency was observed for each compound. However, Me-AZM remained the most effective, with an 
IC50 that was approximately 75-fold more potent than MC, suggesting that Me-AZM is more cytotoxic than 
MC regardless of the oxygen tension in the experiment.  
2.2 Modified alkaline single cell gel electrophoresis (COMET) assay  
A modified COMET assay was used to assess the ability of synthetic AZMs to form DNA crosslinks.24-27 The 
assay investigates the extent of drug-induced DNA crosslinking in individual cells by visualizing and 
quantifying DNA migration following exposure to DNA damaging agents.25 The study examined the 
electrophoretic mobility of DNA from individual cells first treated with MC, Me-AZM, or H-AZM and then 
subsequently treated with hydrogen peroxide. The hydrogen peroxide induces DNA strand breaks, which 
increases the DNA’s electrophoretic mobility and results in the appearance of an elongated “tail” in the 
electropherogram. Agents that sponsor DNA crosslinks prior to hydrogen peroxide exposure hinder migration 
during electrophoresis due to increased DNA fragment size or alterations to DNA contour during migration 
through agarose. This leads to a decreased tail length when compared to cells treated with hydrogen peroxide 
alone.24,27 A smaller value for the “tail extent moment”, which is calculated by multiplying tail length by the 
measured amount of DNA in the tail,24,25 is indicative of increased DNA interstrand, intrastrand, or DNA-
protein crosslinks. 
 
Figure 3. Representative fluorescent images of aerobic Jurkat cells following the modified alkaline COMET assay and SYBR green 
staining. (A) Drug untreated cells: minimal DNA strand breaks control; (B) Drug untreated cells + H2O2: maximal DNA strand breaks 
control; (C-E) MC, H-AZM, Me-AZM treated cells + H2O2. Homologous images for COMET assays performed under hypoxic 
conditions can be found in supplemental content.  
The COMET assay electropherograms show that 10 µM AZM treatment results in decreased DNA mobility 
from peroxide induced strand breaks alone (Figure 3). In Jurkat cells under aerobic conditions, both AZMs 
produced significant reductions in tail extent moments relative to the 100 µM H2O2 treatment control. Me-
AZM and He-AZM treatment produced similar mean tail extent moments (0.26 ± 0.4 and 0.49 ± 0.07, 
respectively), indicating that extensive DNA crosslinks had occurred (Figure 4). Under the same conditions, 
MC produced a tail extent moment (96.0 ± 6.0) that was not statistically different from the 100 µM H2O2 
treatment control, indicating minimal DNA crosslinks. Under hypoxic conditions, Me-AZM and H-AZM 
treatment continued to cause extensive DNA crosslinks (tail extent moments of 0.32 ± 0.29 and 3.6 ± 0.7, 
respectively). However, MC treatment under hypoxic conditions resulted in a slight, but statistically significant 
decrease in tail extent moment (87.0 ± 2.5). This result is consistent with literature reports indicating that the 
extent of crosslinks detected by the COMET is highly dependent upon cell type and drug incubation time,28 and 
high drug concentrations are often required to visualize substantial responses.24,25 
 Figure 4. Modified alkaline COMET assay of Jurkat cells. Tail extent moments are expressed as the mean ± SEM of two experiments 
(n > 50 cells per treatment). * denotes ρ < 0.05 by two-way ANOVA, when compared to the matched (i.e., aerobic or hypoxic) 
peroxide treatment control (Untx + 100 µM H2O2). (Untx = no drug treatment, MC = mitomycin C treated cells, H-AZM and Me-
AZM = aziridinomitosene treated cells.) 
2.3 Hoechst 33342 fluorescence assay 
Prior investigations of DNA crosslinkage by synthetic AZMs were confined to demonstrations of adduct 
formation with purified nucleic acids or oligonucleotides. The COMET assays described above do not 
differentiate between DNA interstrand, intrastrand, or DNA-protein crosslinks. To further establish that AZMs 
could form DNA ICLs in eukaryotic cellular environments, we evaluated DNA modification induced by Me-
AZM and H-AZM in Jurkat cell lines using a Hoechst 33342 fluorescence assay.29-31 When bound to double 
stranded DNA (dsDNA), Hoechst dyes exhibit increased fluorescence compared to single stranded DNA 
(ssDNA). The premise of the assay is that DNA crosslinks lead to increased retention of fluorescent Hoechst 
dye compared to un-crosslinked DNA. Thermal denaturation followed by rapid cooling normally causes DNA 
base pair mismatches that yield extensive regions of ssDNA with decreased Hoechst fluorescence. Covalent 
DNA crosslinks act as anchor points, decreasing the level of base pair mismatches that occur following a series 
of heat denaturation/rapid cooling processes. Thus, more heavily crosslinked DNA will exhibit increased 
recovery of dsDNA character and retention of Hoechst fluorescence.29  
In this study, Me-AZM treatment of Jurkat cells produced a significant increase in the amount of crosslinked 
DNA when compared to similar treatment with MC or H-AZM (Figure 5). The amount of Me-AZM sponsored 
crosslinks per DNA fragment was calculated at 0.55 ± 0.05 and 0.51 ± 0.02 for aerobic and hypoxic cells, 
respectively. These values are 68-fold and 8-fold greater than the crosslinks per DNA fragment sponsored by 
MC treatment. Consistent with our earlier observations, the effects of H-AZM treatment were more modest, 
showing a 13-fold increased amount of crosslinked DNA relative to MC under aerobic conditions. Under 
hypoxic conditions, H-AZM treatment did not produce a significant increase in crosslinked DNA relative to 
MC treatment.  
 
Figure 5. DNA-DNA crosslinks in AZM and MC treated Jurkat cell lines. Cellular DNA was isolated after treatment with 10 µM 
MC, H-AZM, or Me-AZM, the crosslinks per DNA fragment were measured as a decrease in Hoechst 33342 – DNA fluorescence 
relative to untreated cellular DNA. Data presented is the mean ± SEM of two experiments (n = 6). * denotes ρ < 0.05 by two-way 
ANOVA when compared to the matched (i.e., aerobic or hypoxic) untreated control.  
The Hoechst 33342 fluorescence assay results showed that Me-AZM and H-AZM treatment produced DNA 
crosslinks in cells after one hour of treatment under aerobic conditions, whereas only Me-AZM crosslinked 
DNA to a significant extent in an hypoxic environment. MC treatment under aerobic and anaerobic conditions 
produced minimal DNA modification. These results are consistent with our earlier findings demonstrating that 
Me-AZM is the most active DNA-modifying agent of the three compounds, and that hypoxia only minimally 
alters the experimental outcome. Further, AZM-induced DNA ICL formation is consistent with previous reports 
that demonstrated H-AZM treatment of purified DNA and oligonucleotides under non-reductive conditions 
resulted in DNA-DNA crosslinks.16,17 
For H-AZM, there is an apparent discrepancy between the COMET and Hoechst assays in that one shows 
extensive DNA crosslinkage while the other does not. However, proteins are removed during the DNA isolation 
process required for the Hoechst assay, which probably removes DNA containing DPCs from the isolated DNA. 
With the COMET assay, the entire cell is examined under electrophoresis, so this experiment does not 
distinguish between DNA ICLs or DPCs. Thus, if the majority of H-AZM produces DPCs, a reduced tail 
moment on the COMET assay would be observed, but DNA crosslinks would be minimized in the Hoechst 
assay.  
2.4 K-SDS DNA-protein crosslinking assay 
The K-SDS assay has been widely used to study drug sponsored DNA-protein crosslinks (DPCs). Previous 
studies, employing the alkaline elution assay, have shown that MC induces DPCs in mammalian cells,18-20,32 but 
no reports have demonstrated that AZMs induce DPCs in vitro. To determine the potential of AZMs to crosslink 
DNA to protein we used an adaptation of the K-SDS assay first described by Zhitkovitch and Costa.33 Unlike 
the alkaline elution assay, the K-SDS assay conditions cause disassociation of non-covalently bound DNA, and 
selective salt precipitation of DNA-protein adducts to effectively allow separation and quantification of 
covalent DNA-protein complexes.  
 Figure 6. K-SDS assay for DPCs in drug treated Jurkat cells. DPCs were isolated from Jurkat cells after 1.5 h treatment with saline 
(Untx), 3 mM formaldehyde (FA,) or 100 μM concentrations of MC, H-AZM, or Me-AZM. Data is presented as the mean ± SEM of 
three independent experiments (n=9). * denotes ρ < 0.05 by two-way ANOVA when compared to the matched aerobic or hypoxic 
untreated control (no bracket) or when compared to reaction conditions for a given treatment (with bracket). 
The K-SDS assay conducted under aerobic conditions demonstrated that 100 µM Me-AZM and H-AZM 
treatment induced significant increases in DPCs (17-20%) relative to the untreated Jurkat cell control (Figure 6). 
Treatment with 3 mM formaldehyde (FA), a known DNA-protein crosslinking agent, showed the highest % 
DPC (53.2 ± 3.7 %). Cells treated with 100 μM MC did not show significant increases in DPC (7.8 ± 2.3 %) 
formation relative to the untreated control (4.5 ± 1.5 %), indicating these are not the primary DNA 
modifications sponsored by MC. Interestingly, DPC formation for Me-AZM (41.9 ± 5.7 %) was enhanced 
under hypoxia. However, hypoxic conditions failed to significantly improve H-AZM and MC stimulated DPC, 
which remained statistically equivalent to untreated control.  
Previous DNA footprinting studies with H-AZM resulted in high molecular weight, low mobility bands that 
were consistent with DPC formation during nuclease exposure in the assay.17 Since the K-SDS assay is specific 
for detecting chemically induced DNA-protein adducts, our current results with Me-AZM and H-AZM provide 
the first substantive evidence of an AZM sponsored DPC. The lack of significant DPC formation by MC 
contradicts prior studies that report MC stimulated actin crosslinks to DNA.18 This may be due to the increased 
specificity of this particular technique. The K-SDS assay was created for the sole purpose of detecting and 
isolating DPCs produced by crosslinking agents in vivo,33 and is thought to be more stringent than the alkaline 
elution method used in the previous study.18  
In spite of its utility, the K-SDS assay does not discriminate between protein covalently bound to 
monoalkylated DNA or crosslinked DNA. Additionally, the order of binding events is not readily apparent after 
conclusion of the experiment. Additional experiments will be necessary to obtain these mechanistic details. 
2.5 Potential mechanisms for AZM ICL and DPC formation 
While the mechanism of DNA ICL and DPC formation by Me-AZM and H-AZM is currently unknown, we 
envision two reasonable mechanisms that could account for their formation in tumor cells and in reactions with 
DNA in the absence of reductant (Figure 7). The first, Path A, involves acidic activation of the C1 and C10 
electrophilic sites. Rapid acid-catalyzed aziridine ring-opening results in a carbocation that is captured by 
nucleophilic DNA in the minor groove. Next, slow carbamate departure forms an iminium intermediate that 
undergoes a second nucleophilic addition to produce the ICL. The acidic activation mechanism is consistent 
with previous studies demonstrating that H-AZM forms DNA ICLs best under acidic conditions (pH 6) with 
long reaction times (up to 48 hours).16 Also, the acidic mechanism serves to rationalize the increased potency 
and increased DNA-binding efficiency of Me-AZM in cellular systems, reported herein, since incorporation of 
the electron donating methyl group should help stabilize the carbocations formed upon aziridine ring-opening 
and carbamate departure. However, the mechanism is inconsistent with several important observations. First, 
numerous AZMs with varying electronic properties have been reported in the literature, many of which are 
more electron rich than H-AZM,12 and it seems that acidic activation to yield DNA ICLs should have been 
observed with some of these AZMs. Second, the mechanism proposed in path A does not provide an obvious 
route to account for the previously unobserved DPCs. Finally, we have evidence (unreported) that H-AZM 
crosslinks synthetic DNA more efficiently than Me-AZM,34 which contradicts the proposed mechanism. 
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Figure 7. Potential mechanisms for the AZM-induced formation of DNA ICLs and DPCs in absence of reductant. Two 
reasonable mechanisms for the formation of DNA ICLs and DPCs include aziridine opening and carbamate departure via acidic 
activation (Path A, top) and carbamate departure via nucleophilic activation (Path B, bottom). Enzymatic reduction (not shown) in a 
manner analogous to MC may be occurring in cellular systems, but this does not explain the formation of adducts in absence of 
reductant. 
The nucleophilic activation mechanism (Figure 7, Path B) has the notable feature of agreeing with prior reports 
indicating that carbamate departure and subsequent ICL formation requires either extreme acidic conditions (pH 
< 5)35 or reductive activation.10 Also, the mechanism agrees with our own observations to a greater extent and 
invokes the lack of quinone substitution, a key structural feature that is unique to these particular AZMs. In both 
compounds, at least one of the quinone carbon atoms is unsubstituted, which renders the AZMs susceptible to 
Michael addition at that position. Given this, the first step in the hypothesized mechanism involves the standard 
acid catalyzed aziridine ring-opening and DNA monoadduct formation, typical of previously reported AZMs. 
Next, Michael addition by media or a cellular nucleophile results in an intermediate that can tautomerize to a 
leucoaziridinomitosene species (leuco-AZM) where carbamate expulsion and crosslink formation are favored. 
Support for this mechanism is provided by the non-enzymatic activation of mitomycin A by thiols, which has 
been proposed to follow a sequence that is initiated by nucleophilic attack at C7.36,37  
Nucleophilic activation also provides a potential avenue for DPC formation, if the nucleophile facilitating 
activation is a DNA-associated protein. Further, Michael addition into the quinone ring offers an explanation for 
the decreased potency of H-AZM compared to Me-AZM. Structurally, H-AZM affords two quinone 
electrophilic sites, since both C6 and C7 are unsubstituted. In contrast, Me-AZM presents only C7 as an 
electrophilic center. Thus, H-AZM is expected to be a highly reactive Michael acceptor that is more prone to 
nucleophilic sequestration by cell media or other bionucleophiles prior to DNA alkylation. Our HPLC 
decomposition experiments support the increased sensitivity to nucleophiles, as the DMEM cell culture media 
resulted in about 90% decomposition of H-AZM in about 2 hours, whereas Me-AZM resulted in only about 
10% decomposition over the same period of time. Thus, the formation of ICLs and DPCs by both AZMs, along 
with the rapid decomposition of H-AZM, are indicative of Path B as the more likely mechanism for DNA 
adduct formation in absence of reductant. 
3. Conclusion 
Two synthetic AZMs, differing only by the presence or absence of a quinone ring methyl at C6, were examined 
for their ability to modify human cellular DNA. While both Me-AZM and H-AZM demonstrated DNA 
modification, Me-AZM exerted more potent antiproliferative effects against cancer cell lines that were 
consistently better than the effects of MC. The results of the modified COMET assays, Hoechst fluorescence, 
and K-SDS assays suggest that the antiproliferative effects could in part be attributed to drug sponsored DNA 
damage that yield either ICLs and/or DPCs. It is noteworthy that Me-AZM treatment produced much stronger 
antiproliferative effects and more DNA adducts than H-AZM. Potentially, H-AZM showed lesser effects 
because the unsubstituted quinone ring is a more reactive target for nucleophilic addition, which renders it more 
prone to decomposition and decreased half-life in the cellular environment or extracellular media. The methyl 
group at C6 in Me-AZM may sterically hinder nucleophile accessibility to the quinone ring, thus improving the 
half-life of the AZM by preventing non-productive reactions with other biomolecules outside the context of the 
DNA. Future experiments will be directed towards determining the DNA alkylating abilities of additional AZM 
analogs with chemical modification at the C6 and C7 positions, characterizing the DNA-AZM adducts that are 
produced in reactions with DNA and DNA-associated proteins in both cell cultures and in cell-free 
environments, and evaluating the role of quinone reduction in DNA crosslinking experiments. 
4. Materials and Methods 
4.1 Materials 
Me-AZM and H-AZM were synthesized in our laboratory according to previously reported methods.17,38 MC 
was purchased from Cayman Chemical (Ann Arbor, MI). Resazurin sodium salt was acquired from Acros 
Organics (Fairlawn, New Jersey). Anhydrous dimethyl sulfoxide (DMSO) was obtained from Sigma (St. Louis, 
MO). Hoechst 33342 and 10,000x SYBR Green were obtained from Invitrogen (Carlsbad, CA). HyClone 
growth media (RPMI-1640 and Dulbecco’s Modified Eagles Medium (DMEM) and penicillin/streptomycin 
were obtained from Thermo Scientific (Waltham, MA). Fetal Bovine Serum (FBS) was purchased from Fisher 
Scientific (Hampton, NH). Ultracleen Tissue & Cells DNA Isolation Kit was obtained from Mo Bio 
Laboratories Inc. (Carlsbad, CA). Proteinase K was purchased from AMRESCO (Solon, OH). The COMET 
Assay Kit was purchased from Trevigen (Gaithersburg, MD).  
4.2 Cell culture methods and drug stocks 
Aerobic Conditions: Six different human cell lines were used to evaluate the potency of the AZMs and MC. 
The three suspension (Jurkat, HUT-78, HL-60) and three adherent cancer cell lines (HeLa, T47D, HepG2) were 
the generous gifts from Drs. Denise Wingett, Cheryl Jorcyk and Kristen Mitchell, all from Boise State 
University. The Jurkat and T47D cells were cultured in RPM1-1640 supplemented with 10% fetal bovine serum 
(FBS), penicillin (100 U/mL) and streptomycin (100 µg/mL) (pen/strep). HeLa and HepG2 cell lines were 
grown in Dulbecco’s Modified Eagles Medium (DMEM) containing 10% FBS with pen/strep. HL-60 and HUT-
78 cell lines were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 20% FBS and 
pen/strep. All cell lines were grown at 37 ºC in 5% CO2. Stock solutions of Me-AZM, H-AZM, and MC were 
prepared in DMSO and stored at -80 ºC prior to use. The stock solutions were thawed, quickly diluted in sterile 
nanopure water or 1x PBS to achieve working concentrations for experiments, and rapidly added to cells in 
order to minimize decomposition prior to AZM delivery. 
Hypoxic Conditions: To induce hypoxia, a method previously described by Wang et al. with minor 
modifications was used.39 The appropriate number of cells were transferred to well-ventilated flat bottom T-25 
culture flasks in a MIC-101 Modular Incubator Chamber (Billups-Rothberg, Inc., Del Mar, CA) that was 
continuously purged with 95% N2/5% CO2 for 15 min to effect complete gas exchange. The chamber was 
sealed and the cells incubated for an additional hour at 37 °C. PBS used for Me-AZM, H-AZM, and MC drug 
dilutions was sparged with 95% N2/5% CO2 prior to addition of the appropriate compound. The AZMs and MC 
were delivered to the cells by quickly breaking the seal of the anaerobic chamber and pipetting directly into the 
flasks. The anaerobic chamber was resealed and purged for another 15 min with the 95% N2/5% CO2 gas 
mixture. The cells were incubated in the sealed anaerobic chamber at 37 °C for the time required for each given 
experiment. 
4.3 Resazurin reduction assay 
Adherent cells were harvested at high confluency during log phase of growth. Briefly, cells were washed with 
sterile PBS and trypsinized for 5 min. Cells were collected by centrifugation (150-250 xg /5 min) and 
resuspended in the appropriate medium supplemented with FBS and 1% penicillin/streptomycin. Sterile 96-well 
plates were seeded with 8,000 cells/well and then incubated for 24 h at 37 °C in 5% CO2. The media was 
removed and replaced with fresh media containing dilutions of Me-AZM, H-AZM, MC, or vehicle to achieve 
the desired concentration gradient. Suspension cell lines were also plated at 8,000 cells/well. After drug 
addition, cells were incubated for an added 48 h, at which time 20 μL of 0.1% resazurin in sterile PBS was 
added into each well and incubated for an additional 4-24 h at 37 °C in 5% CO2. Fluorescence values 
(excitation/emission: 530/590 nm) were then obtained using a BioTek Synergy HT plate reader (BioTek, 
Winooski, VT). Fluorescence data was plotted as a percentage of the untreated value using GraphPad Prism and 
fit to a non-linear regression with log (inhibitor) vs. response for determination of IC50 values. Data are 
presented as the mean (± SEM) for at least three independent experiments with at least three replicate wells 
used in each experiment. 
4.4 Decomposition of Me-AZM and H-AZM in DMEM cell culture media 
HPLC analysis was conducted using an Agilent 100 series HPLC equipped with a 50 mm x 4.6 mm with 5 μm 
pore size hypersil GOLD phenyl column and detected at 254 and 480 nm. HPLC samples were prepared as 
quickly as possible (ca. < 5 min) to minimize decomposition by adding Me-AZM and H-AZM stock solutions 
in DMSO to filter-sterilized DMEM containing 10% FBS with pen/strep to yield a final concentration of 250 
µM for Me-AZM and 250 µM for H-AZM. The solutions were vortexed, filtered into HPLC vials using 0.2 
μM pore size PTFE syringe filters. The vials were placed in an auto-sampler and 20 μL of solution was injected 
into the HPLC every 15 min until near complete decomposition was observed. HPLC-grade acetonitrile pH 7.2 
Tris buffer were prepared as a mobile phase A and B, respectively. Gradients were conducted flow rate at 1.0 
ml/min for 15 minutes with the following linear program: t= 0 min (30%; A, 70%; B), t= 10 min (70%; A, 30%; 
B), t= 12 min (70%; A, 30%; B), t= 12.1 min (30%; A, 70%; B), and t= 15 min (30%; A, 70%; B). The HPLC 
retention times for H-AZM and Me-AZM were 2.9 min and 6.6 min, respectively. Chromatograms are 
included in the supplemental content.   
4.4 Modified alkaline single cell gel electrophoresis (COMET) assay  
The alkaline COMET Assay was performed according to the manufacturer’s protocol (Trevigen, Gaithersburg, 
MD) with minor modifications. Briefly, Jurkat cells were harvested, washed once with complete RPMI-1640, 
and reconstituted to a final density of 1 x 105 cells/mL. Cells were then either treated with a final concentration 
of either 10 µM Me-AZM, H-AZM, MC, or 1x PBS for one hour at 37 °C in 5% CO2 with agitation every 15 
min. After one hour, the cells were harvested by centrifugation, washed once in 1x PBS, then resuspended in 
100 µM hydrogen peroxide in 1x PBS for 20 minutes at 4 °C. After treatment, cells were harvested by 
centrifugation at 4 °C (5 min, 150 xg), washed twice, and resuspended in 1 mL of 1x PBS. A 50 µL portion of 
the cell suspension was combined with 500 μL of 37 °C low melting point agarose, and a 50 μL portion spread 
evenly on the COMET slide. COMET slides were then allowed to solidify at 4 °C for 30 minutes in the dark, 
and then were submerged in lysis solution overnight at 4 °C in the dark. Next, the slides were submerged in a 
freshly prepared alkaline DNA unwinding solution (pH >13) for 20 min at 22 °C in the dark, and then subjected 
to electrophoresis (20V, ~300 mA) for 30 min at 4 °C under minimal light conditions. The slides were 
submerged in DI water twice (5 min), once (5 min) with 70% ethanol, dried at 37 °C for 15 min, and then 
stained with 1x SYBR Green solution in 10 mM Tris, 1mM EDTA (pH 8.0) for 30 minutes at 22 °C in the dark. 
Slides were then submerged into DI water to remove excess SYBR green and dried for 1-2 hours at 37 °C.  
COMET slides were examined and images captured on an AMG Evos fluorescence microscope (Mill Creek, 
WA) using the 10x objective and GFP filter. Analysis for tail extent moment was performed using the 
OpenComet plugin for ImageJ (NIH),40,41 and tail extent moments (mean ± SEM) plotted in GraphPad Prism 
using a minimum of 50 COMET analyses per drug treatment group from two experiments. 
4.5 Hoechst 33342 fluorescence assay 
The Hoechst fluorescence assay was adapted from a previously reported DNA crosslinking assay.29 Jurkat cells 
(~5-6 x 106 cells) were treated with either 10 μM MC, Me-AZM, H-AZM or 1x PBS for 1 hour.  DNA from 
was then isolated using the Mo Bio Ultracleen Tissue & Cells DNA Isolation Kit according to the 
manufacturer’s instructions. Samples for the assay were prepared in the dark by combining isolated cellular 
DNA (3,750 ng) with 300 µL of 1.0 µg/mL Hoechst 33342 dye in nanopure H2O. The total volume was brought 
to 3 mL with 0.5x TE buffer. Sample fluorescence was measured using an excitation/emission wavelength of 
360/460 nm. A fluorescence control reaction consisted of 3 mL 0.5x TE buffer containing only 0.1 µg/mL 
Hoechst 33342 dye. The retention of fluorescence was then measured after subjecting samples to a heat/chill 
process as follows: 5 min in a 96-98 °C water bath, immediate chilling in an ice-water bath for 5 min, followed 
by incubation in a room temperature water bath for 5 min. The fluorescence measurement was repeated and the 
crosslinked fraction determined using Equation 1:  
Cross-linked fraction  =  
𝐸𝐸𝐴𝐴
𝐸𝐸𝐵𝐵
   −  𝐶𝐶𝐴𝐴
𝐶𝐶𝐵𝐵
1  −  𝐶𝐶𝐴𝐴
𝐶𝐶𝐵𝐵
               Equation 1 
 
Where, CA = fluorescence of control sample after heat/chill, CB = fluorescence of control sample before heat 
chill, EA = fluorescence of experimental sample after heat/chill, and EB = fluorescence of experimental sample 
before heat/chill. 
Crosslinked fraction values were converted to crosslinks per DNA fragment using Equation 2: 
 
  Crosslinks per DNA fragment =    -ln(1-X)   Equation 2 
 
Where X = the crosslinked fraction, as determined using Equation 1. 
Data was analyzed in Microsoft Excel and GraphPad Prism. Values represent the mean (± SEM) of two 
independent DNA isolations with measurements conducted in triplicate for each isolation. 
4.6 K-SDS DNA-protein crosslinking assay 
DNA-protein crosslinks were determined using a method adapted from Zhitkovitch and Costa.33 Briefly,  Jurkat 
cells (2 x 105 cells) were treated for 1.5 h at 37 °C in complete RPMI-1640 (for AZM and MC treatment) or 
serum-free RPMI-1640 (for 3mM formaldehyde treatment). Two different AZM and MC drug concentrations, 
10 μM and 100 μM, were used to show a concentration dependent increase in DPCs. After treatment, cells were 
washed twice with ice-cold PBS, resuspended in 20 μL PBS, and then lysed by addition of 100 μL 2% SDS in 
20mM Tris-HCl solution (pH 7.5). The lysed samples were then frozen at -20 °C. After thawing, samples were 
vigorously vortexed for 10 s, warmed to 65 °C for 10 min and then 100 μL of a 200 mM KCl/20 mM Tris-HCl 
(pH 7.5) solution was added. The DNA was sheared by passing each sample through a 200 µL pipet tip five 
times. Samples for K-SDS precipitation were formed by chilling samples on ice for 5 min and collecting by 
centrifugation at 3000 xg for 5 min. The supernatant from each sample was saved in individual microfuge tubes 
and the pellets subjected to three rounds of precipitation: pellets were resuspended in 200 µL 100 mM KCl/20 
mM Tris-HCl (pH 7.5), heated to 65 °C for 10 min, placed on ice for 5 min and centrifuged at 3000 xg for 5 
min. The pellets were resuspended in 0.2 mg/mL proteinase K solution in 100 mM KCl/20 mM Tris-HCl (pH 
7.5) and incubated at 55 °C for 3 h. After incubation, the samples were placed on ice for 10 min to allow the 
precipitation of SDS. Samples were centrifuged at 10,000 xg for 10 min and the supernatants collected. The 
quantity of protein-linked and non-linked DNA was measured using SYBR Green dye (Invitrogen, Carlsbad, 
CA) and comparing fluorescence values against a known DNA standard. The percent DPC was calculated as % 
DPC = [protein-linked DNA/(non-linked DNA + protein-linked DNA)] x 100%. 
Supplementary data 
Supplementary data (representative resazurin antiproliferative activity profiles, HPLC chromatograms obtained 
as part of decomposition studies, and representative fluorescent images of anaerobic Jurkat cells following the 
modified alkaline COMET assay and SYBR green staining) associated with this article can be found, in the 
online version, at http://dx.doi.org..... 
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